title: Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia.
abstract: Medication nonadherence has been associated with persistence of psychotic symptoms, relapse, and hospitalization in patients with schizophrenia. Patients with untreated psychosis are significantly less likely to achieve remission, whereas antipsychotic drug adherence has been associated with recovery. As such, adherence to antipsychotic drug treatment is a key issue for nurses and treatment team members caring for patients who typically are on chronic, progressive disease course. Long-acting injectable (LAI) anti-psychotic drugs, developed to improve adherence and provide and alternative antipsychotic drug treatment fro schizophrenia, have been associated with improved treatment outcomes including reduction of relapse rates approximately 30% and reduction in hospitalizations. However, LAI antipsychotic drugs remain underutilized in the United States despite a growing body of literature supporting positive outcomes of LAI versus oral antipsychotic drugs. Mental health nurses are in a key position to support improved adherence inpatients with schizophrenia through use of practical educational strategies that help patients, family members, and health care providers better understand and manage treatment.
authors.affiliation: Richmond Behavioral Health Authority, Richmond, VA, USA. mortonk@rbha.org
authors.forename: N
authors.initials: N
authors.lastname: Kirk Morton
authors.forename: Donna
authors.initials: D
authors.lastname: Zubek
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage*; D001569:Benzodiazepines; D003692:Delayed-Action Preparations; D005476:Fluphenazine / Q000031:analogs & derivatives; D006220:Haloperidol; D006801:Humans; D007267:Injections; D007555:Isoxazoles; D055118:Medication Adherence; D000077152:Olanzapine; D000068882:Paliperidone Palmitate; D010168:Palmitates; D018967:Risperidone; D012559:Schizophrenia / Q000188:drug therapy* / Q000451:nursing
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D007555:Isoxazoles; D010168:Palmitates; D001569:Benzodiazepines; C011825:fluphenazine depot; D006220:Haloperidol; D018967:Risperidone; D000077152:Olanzapine; D000068882:Paliperidone Palmitate; D005476:Fluphenazine